The role of antibodies in enzyme treatments and therapeutic strategies
- 1 March 2015
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2) , 183-194
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfaseOrphanet Journal of Rare Diseases, 2013
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brainOrphanet Journal of Rare Diseases, 2013
- Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment OutcomePLOS ONE, 2012
- Predicting cross‐reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experienceAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2012
- Heparin cofactor II‐thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short‐ and long‐term treatment effects in mucopolysaccharide diseasesJournal of Inherited Metabolic Disease, 2010
- Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human N‐acetylgalactosamine 4‐sulfataseJournal of Inherited Metabolic Disease, 2010
- Sorting of lysosomal proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kgPLOS ONE, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004